HIV/AIDS Clinical Trials in San Antonio

Showing 21-40 of 374 trials

Behavioral Economic Intervention to Improve HIV Behaviors in Sexual Minority Individuals

NCT06745947

This research study is testing a new behavioral therapy called Episodic Future Thinking or EFT can help people reduce drug use and risky sexual behaviors while helping them adhere to their HIV prevention medication (PrEP). Participants will be randomly assigned to one of two groups. One group will receive standard care, which includes counseling on HIV prevention, drug use reduction, and sexual health. The other group will receive standard care plus a new program called Episodic Future Thinking (EFT), where participants will think about and plan for their future goals using a mobile app and counseling sessions. Study procedures that are not part of regular care include filling out surveys, providing blood, urine, and swab samples for testing, and using the EFT app.

HIV Prevention

The University of Texas Health Science Center at San Antonio60 participantsStarted Mar 2025

San Antonio, Texas, United States

COMPLETEDNA< 1 mile

Feasibility of Positive Links for Youth Care Engagement Intervention

NCT05689515

A small pilot study to assess feasibility and acceptability of the PL4Y intervention.

HIV Antibody Positivity

The University of Texas Health Science Center at San Antonio30 participantsStarted Feb 2023

San Antonio, Texas, United States

Active Not RecruitingPhase 374 miles

A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF

NCT05911360

The study aims at evaluating the maintenance of virologic suppression of dolutegravir/lamivudine (DTG/3TC) fixed dose combination (FDC) at Week 48 post-switch from bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in participants living with Human Immunodeficiency Virus Type 1 (HIV-1) who are of at least 50 years of age and above.

HIVHIV Infections

ViiV Healthcare205 participantsStarted Jan 2023

Phoenix, Arizona, United States • Bakersfield, California, United States • Palm Springs, California, United States +53 more locations

Behavioral Economic Intervention to Improve HIV Behaviors in Sexual Minority Individuals

Feasibility of Positive Links for Youth Care Engagement Intervention

A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF

HIV/AIDS Trials in Other Cities

A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen

PRO 140 in Treatment-Experienced HIV-1 Subjects

Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission

The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE

A Study of the Safety, Tolerability, and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)

A Study to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of VH3739937 in in Treatment-Naive Adults Living With HIV-1

Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma

Anal High-risk HPV, HSIL, and Microbiome Among Hispanic Peoples Living With HIV (PLWH)

A Study of VRC07-523LS, PGT121.414.LS, and PGDM1400LS Broadly Neutralizing Monoclonal Antibodies Given Intravenously in Adult Participants Without HIV

Information Visualizations to Enhance HIV-related Communication

A Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of PGDM1400LS Alone and in Combination With VRC07-523LS and PGT121.414.LS in Healthy, HIV-uninfected Adult Participants

VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions

Development of a Health-Related Symptom Index for Participants With and Either Treated or Monitored for Anal High-Grade Squamous Intraepithelial Lesions

Islatravir and Methadone Pharmacokinetics (MK-8591-029)

Incidence of HIV Infection in Screening Indian Men Who Have Sex With Men

Other Conditions in San Antonio